Live Breaking News & Updates on Cutaneous Lupus Erythematosus Disease Area

Stay updated with breaking news from Cutaneous lupus erythematosus disease area. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Could Innate Immune Dysfunction Drive Lupus?

Japanese researchers open new front in SLE therapy ....

John Gever , Yoshiya Tanaka , Environmental Health , University Of Occupational , Cutaneous Lupus Erythematosus Disease Area , Severity Index , Physician Global Assessment , Managing Editor ,

Novel Lupus Approach Yields Mixed Results in Early Trial

Hints of benefit seen in patients with more active disease ....

United States , James Posada , John Gever , British Isles Lupus Assessment Group , Resolve Therapeutics , Cutaneous Lupus Erythematosus Disease Area , Severity Index , Lupus Science , Activity Index , Managing Editor , Sci Med ,

Emerging Therapies Foretell New Era for Cutaneous Disorders

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders. ....

United States , Anthony Fernandez , Drug Administration , American Academy Of Dermatology , Cleveland Clinic , Cutaneous Lupus Erythematosus Disease Area , Severity Index , Cutaneous Dermatomyositis Disease Area , New England Journal , American Academy , Systemic Lupus Erythematosus Sle Erythaematosus , Cutaneous Lupus Erythematosus Erythaematosus , Biologic Therapy , Interferon Beta , Fn Beta , Interferon Beta , Monoclonal Antibody , Multiple Sclerosis Ms , S Multiple Sclerosis , Clinical Research ,

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Region Flamande , Sandra Cauwenberghs , Van Gijsel , Daniele Dambrosio , Marieke Vermeersch , British Isles Lupus Assessment Group , Exchange Commission , Composite Lupus Assessment , Cutaneous Lupus Erythematosus Disease Area , Severity Index Activity , Lupus Low Disease Activity State , Danieled Ambrosio , Therapeutic Area Head Immunology , Aktien Sie ,

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases. ....

Region Flamande , Daniele Dambrosio , Marieke Vermeersch , Sandra Cauwenberghs , Van Gijsel , British Isles Lupus Assessment Group , Exchange Commission , Composite Lupus Assessment , Cutaneous Lupus Erythematosus Disease Area , Severity Index Activity , Lupus Low Disease Activity State , Danieled Ambrosio , Therapeutic Area Head Immunology ,